X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in pre-clinical development.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 16, 2022
Details:
LogicBio's gene delivery platforms, coupled with Alexion’s advancements with AstraZeneca, will drive future scientific possibilities and next generation medicines to treat rare genetic diseases.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 03, 2022
Details:
LogicBio's SUNRISE trial is a first-in-human, open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety, tolerability, and preliminary efficacy of a single intravenous infusion of LB-001 in pediatric patients with MMA.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
LB-001 is an investigational, first-in-class, single-administration, genome editing therapy for early intervention in methylmalonic acidemia (MMA) using LogicBio's proprietary GeneRide® drug development platform.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
LB-001, an investigational, single-administration, genome editing therapy for early intervention in methylmalonic acidemia has been on clinical hold for Phase 1/2 SUNRISE clinical trial because of the first infant to receive the therapy suffered a serious adverse event.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2022
Details:
Under the terms of the agreement, CANbridge is granted an option to an exclusive license for LB-001, an investigational in-vivo gene editing technology based on LogicBio's GeneRideTM platform for the potential treatment of methylmalonic acidemia (MMA) in Greater China.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CANbridge Pharmaceuticals
Deal Size: $591.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration April 27, 2021
Details:
U.S FDA has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). Company plans to initiate, advance and complete its Phase 1/2 clinical trial for LB-001 in MMA.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
LogicBio intends to use the net proceeds from the offering to support clinical development of LB-001, to progress the development of its GeneRide and Next Generation Capsid platforms, to expand its pipeline of product candidates into other indications.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 30, 2020
Details:
The SUNRISE trial is a multi-center, open-label, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with MMA characterized by methylmalonyl-CoA mutase gene (MMUT) mutations.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: LB-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
LogicBio's presentation will highlight results of treatment of Juvenile Mice with methylmalonic Acidemia (MMA) by targeted integration of MMUT into Albumin using a Promoterless AAV Vector.
Lead Product(s): LB-001
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
